Lifecore Biomedical Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
3analysts covering
FY Revenue (est.)
$121.5Mnext fiscal year
FY EPS (est.)
-$1.01next fiscal year
Monitoring Framework
Key Performance Indicators
Total Revenue Quarterly23.2MTarget: 120000000 - 125000000
Adjusted EBITDA Quarterly1MTarget: 20500000 - 25000000
Late-Stage Pipeline Additions Monthly7.0Target: Continuous expansion of late-phase and commercial site transfers
Watch Items
- Series A Preferred Stock Redemption ExposureTrigger: June 29, 2026 redemption deadlineAction: Monitor refinancing, restructuring, or extension agreements to address the $50.2 million redemption exposure.
- Commercial Site Transfer ProgressTrigger: 24-month timeline to commercial revenueAction: Track technical transfer milestones and process performance qualification (PPQ) batches for newly signed aesthetics and neurology programs.
- Capacity Utilization RampTrigger: Increase from 20% to midterm target of 40%Action: Evaluate onboarding efficiency of new biopharmaceutical customers to leverage the $300 million annual revenue-generating capacity.
Research as of 20 Jun 2026